Everything tagged "pharmaceuticals" across the TickerSpark archives.
6 articles
Gilead’s HIV franchise is accelerating, with Yeztugo, Trodelvy, and a stronger pipeline offsetting pressure in Veklury and cell therapy. The stock looks attractive for moderate-risk investors with a medium-term horizon.
Sanofi combines strong Dupixent momentum, improving margins, and solid cash generation with a more leveraged balance sheet and a valuation that looks fair rather than cheap. The result is a patient Hold case for medium-term investors.
GSK is leaning on specialty medicines, Shingrix, and a strong HIV franchise to offset declines in legacy categories. The stock looks fairly valued with modest upside, making it more of a steady Hold than a high-conviction buy.
Regeneron earns a Buy on strong Dupixent momentum, rising free cash flow, and a valuation that still leaves room for upside. EYLEA erosion remains the key offset, but the pipeline and capital returns support the medium-term case.
Novo Nordisk remains a premier cardiometabolic franchise, but near-term pricing pressure and a weak 2026 outlook are tempering the story. The stock looks attractive for patient investors who can look through the reset and wait for obesity and pipeline reacceleration.
Merck combines elite cash generation with a growing pipeline, but KEYTRUDA still drives nearly half of sales. The stock looks like a quality compounder as new launches help reduce concentration risk.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime